Long-term follow-up for vaccines may seem to be a distant concern when clinical trials are just beginning, but it can be critical to have a plan for follow-up at the outset. Learn considerations for follow-up design, s...

2025 has seen both the EMA and the FDA publish new position papers and opinions on streamlining the trial process for biosimilars. On the surface, reducing reliance on comparative efficacy trials has the potential to sav...

There is great excitement following the announcements by the FDA and EMA around streamlining the biosimilar trial process. They promise to reduce the burden on developers and therefore increase the number of more afford...

USP compounding may be fast — but is it costing you quality, compliance, and insight? In this insightful session, our experts discussed: - Why GMP manufacturing offers a strategic edge in early phase trials - Real-worl...

Bringing together safety and efficacy data from multiple studies can be complex. This blog outlines practical approaches to preparing an Integrated Summary of Safety and Efficacy (ISS/ISE) that supports clear, consiste...

ICON is proud to be part of #SCDMIndia, happening 4–6 December in Hyderabad. Meet us at booth \#22 and discover how our team is shaping the future of clinical data management through innovation and expertise. Don’t miss ...

To increase engagement and retention in clinical trials, reduce burden on participants. By enabling participation from the comfort of home, digital health technologies help: - Improve retention - Increase diversity - ...

Join ICON for “Science on Tap” — an evening of discovery, discussion, and holiday cheer! Explore cutting-edge research in precision medicine and bioanalytical laboratory innovation with our expert scientists. If you ar...

Today, on World AIDS Day, we honour the collective progress to combat the HIV epidemic and confront enduring challenges. ICON’s new whitepaper explores how complex biological and social barriers can confound HIV contro...

Don’t miss out on strategies that could transform your site engagement approach. On 3 December at 10am ET, global experts will share evidence-based methods to ease site burden, accelerate activation, and boost enrolment....

According to WHO, HIV remains a major global public health issue, having claimed an estimated 42.3 million lives to date. As a leader in healthcare research, ICON is committed to raising awareness about the importance ...

ICON is committed to raising awareness and generating change for people worldwide living with #HIV and #AIDS, their families and carers. Learn how we can support your infectious disease trials today: https://ow.ly/GMBY50...